Senior Director
Janssen Research & Development LLC
Indrajeet Singh is currently Associate Scientific Director at Janssen Pharmaceuticals. Before joining Janssen in 2015, he was previously employed at Amgen in Thousand Oaks, CA and Abbott Labs in Chicago, IL.
He earned his PhD in Chemical and Biological Engineering from University at Buffalo (UB), NY in 2009. For his PhD research work on thrombosis and hemostasis, in 2008 he was awarded with National Perkin Scholarship by Society of Chemical Industry America International Group.
After completing his PhD, he was a postdoctoral associate in the Department of Pharmaceutical Sciences from 2009-2011 at UB. He has more than 10 years of professional research experience in studying the effect of pharmacology in various therapeutic areas including oncology, hematology and neuroscience. He has more than 8 years of immuno-oncology clinical development experience with various CD3 redirection platforms including CAR-T (chimeric antigen receptor T cells) and Bi-specifics antibody (duo-body, DART, BiTE etc) focused on early and late clinical pharmacology strategy, clinical pharmacokinetics (PK) & pharmacodynamics (PD), and regulatory submissions. He has published in several peer reviewed journals, presented his work at several clinical conferences, chaired multiple external scientific sessions. He has been invited guest speaker at several conferences including FDA workshop on CAR-T cell therapy.